Despite achieving optimal LDL-C levels with statin therapy, the risk of cardiovascular events
persists in the majority of dyslipidemic patients. In particular, patients with mixed …

Background Statins are the standard-of-care therapy for reducing low-density lipoprotein
cholesterol (LDL-C) levels; however, combination with other lipid-modifying agents may be …

Patients with mixed (atherogenic) dyslipidemia have multiple lipid abnormalities, including
low HDL-C and elevated TG, LDL-C, non-HDL-C, and ApoB. Single agent lipid therapy may …

Background Patients with mixed dyslipidemia characterized by elevated low-density
lipoprotein cholesterol (LDL-C), elevated triglycerides (TG), and reduced high-density …

BACKGROUND: Goal/desirable lipid levels are underachieved in patients with mixed
dyslipidemia. These patients may have substantial residual risk of cardiovascular disease …

Introduction: Patients with mixed dyslipidemia are presented with high levels of low-density
lipid cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipid cholesterol (HDL …

Patients with mixed dyslipidemia have a higher risk of atherosclerotic coronary heart
disease than patients with isolated elevated LDL-C. Evidence-based guidelines target LDL …

Mixed dyslipidemia, characterized by a lipid triad of elevated triglycerides (TG), elevated low-
density lipoprotein-cholesterol (LDL-C) and reduced high-density lipoprotein-cholesterol …

The aim of the study was to compare the efficacy of high-dose rosuvastatin, low-dose
rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega-3 fatty acids with regard …

Background Use of a statin at a standard dose may be insufficient for the treatment of mixed
dyslipidaemia. Whether switch to the highest dose of rosuvastatin (40 mg) or add‐on …